This study is a 2-arm, double blinded, randomised clinical trial where 40 participants will be assigned 1:1 to insulin treatment alone (control) or insulin treatment and tirzepatide treatment for 32 weeks. The primary objective is to demonstrate that tirzepatide treatment, dose incremented to 15mg QW for 32 weeks adjunctive to insulin treatment can reduce body weight in patients with T1D and overweight or obesity when compared to insulin treatment alone. The secondary objective is to demonstrate that tirzepatide treatment, dose incremented to 15mg QW for 32 weeks can improve glycaemic control (measured by hbA1c), improve time in range, reduce insulin requirements, and reduce the severity of comorbidities in people with obesity and T1D. This trial includes a 6 month follow-up period.

Start Date01 Dec 2026

Sponsor / Collaborator

Royal North Shore Hospital

NCT07468552

/ Not yet recruitingPhase 2IIT

Randomized, Double-Blind, Placebo-Controlled Pilot Trial of Tirzepatide for Treatment of Cannabis Use Disorder (CUD)

The purpose of this randomized, double-blind, placebo-controlled, multi-site clinical trial is to evaluate the safety and efficacy of tirzepatide in a sample of 100 patients diagnosed with moderate or severe CUD by DSM-5 criteria.

Start Date15 Nov 2026

Sponsor / Collaborator

National Institute on Drug Abuse

100 Clinical Results associated with Tirzepatide

100 Translational Medicine associated with Tirzepatide

100 Patents (Medical) associated with Tirzepatide

2,048

Literatures (Medical) associated with Tirzepatide

31 Dec 2026·JOURNAL OF MEDICAL ECONOMICS

Enhancing economic modelling in obesity: integrating novel type 2 diabetes progression & obstructive sleep apnea remission – a UK case study

Article

Author: Zimner-Rapuch, Sarah ; Annemans, Lieven ; van Hest, Naomi ; Johansson, Erin ; Wilding, John P. H. ; Grist, Josephine ; Spaepen, Erik

PURPOSE:

This study presents an updated health economic model for evaluating the long-term cost-effectiveness of interventions in overweight and obesity, integrating new clinical evidence from the SURMOUNT clinical trial programme and methodological advancements in type-2 diabetes and obstructive sleep apnea (OSA) modelling.

PATIENTS AND METHODS:

An updated individual patient simulation model evaluated the costs and long-term clinical outcomes of tirzepatide (5, 10, 15.0 mg) versus diet and exercise (D&E) alone in patients with a body mass index (BMI) ≥30 kg/m² (obesity), or BMI ≥27 to <30 kg/m² (overweight) + ≥1 obesity-related complication with a UK healthcare perspective. Key improvements over a previously published model were introduced, including modelling remission and progression of OSA, capturing realistic patterns of D&E discontinuation, incorporating HbA1c as a continuous cardiometabolic endpoint and transition to R-based implementation over VBA. Primary results include incremental cost-effectiveness ratios (ICERs; cost/QALY), costs, life years gained and quality-adjusted life years (QALYs). Secondary outcomes including clinical outcomes, random seed and cohort convergence, deterministic sensitivity results and run time were also calculated.

RESULTS:

The refined model predicted that all tirzepatide doses were cost-effective compared to D&E at a £20,000/QALY gained WTP (willingness-to-pay) threshold (ICERs: £8,327-£10,157). Refined estimation of long-term D&E discontinuation and OSA remission likely contributed to lower incremental costs, higher QALYs, and reduced ICERs compared with the previous model, aligning outcomes more closely with expected benefits from weight management treatment. Transitioning to R-based implementation reduced run time (e.g. by 4.52 h for deterministic sensitivity analyses) and enhanced model stability in all analyses conducted.

CONCLUSION:

This enhanced economic model represents a significant advancement in the evaluation of obesity pharmacotherapy, designed to enhance clinical relevance, technical robustness, and increase usability. It supports evidence-based decision-making for chronic weight management treatment in the UK, and beyond, while offering a scalable platform for future therapeutic evaluations.

31 Dec 2026·JOURNAL OF MEDICAL ECONOMICS

Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK

Article

Author: Kanumilli, Naresh ; Evans, Jerome ; Cattin, Juliette ; Debackere, Nele ; Osumili, Beatrice ; Buckingham, Mike ; Hunt, Barnaby ; Webb, Joanne ; Nowakowski, Piotr

INTRODUCTION:

Tirzepatide is a treatment for type 2 diabetes associated with improvements in glycemic control and weight loss, and a low risk of hypoglycemia when not used in combination with insulin or insulin secretagogues. A cost to target analysis of tirzepatide 5, 10 and 15 mg versus subcutaneous semaglutide 1 mg in the UK setting was performed, calculating the annual pharmacy cost per patient treated to six composite endpoints combining glycemic control (glycated hemoglobin [HbA1c] ≤ 6.5% [48 mmol/mol] and <7.0% [53 mmol/mol]) with weight loss (≥5%, ≥10%, ≥15%) and avoidance of hypoglycemia. The costing analysis was based on the tirzepatide costs appraised by NICE as part of TA924.

METHODS:

The proportions of patients achieving composite treatment targets with tirzepatide and semaglutide (both in combination with metformin) were taken from a post-hoc analysis of the SURPASS-2 clinical trial (N = 1,845). Costs per patient treated to target were calculated by dividing the annual treatment costs associated with each intervention by the proportion of patients achieving the treatment target with each intervention.

RESULTS:

Tirzepatide 5, 10 and 15 mg were associated with a lower pharmacy cost per patient achieving treatment target than semaglutide 1 mg for the majority of endpoints evaluated. Differences became greater at more strict treatment targets. For example, the cost per patient achieving HbA1c ≤6.5%, weight loss ≥15%, and no hypoglycemia was GBP 5,650, GBP 8,665 and GBP 9,462 lower with tirzepatide 5, 10 and 15 mg, respectively, compared with semaglutide 1 mg over a 1-year time horizon. The only endpoint where semaglutide 1 mg was associated with a lower cost per patient achieving target was HbA1c <7.0%, weight loss ≥5%, and no hypoglycemia.

CONCLUSIONS:

Compared to semaglutide, tirzepatide was associated with a lower annual pharmacy cost per patient with diabetes achieving treatment target in the UK for the majority of endpoints, with greater differences at more strict treatment targets.

31 Dec 2026·JOURNAL OF MEDICAL ECONOMICS

Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial

Article

Author: Zimner-Rapuch, Sarah ; Kirk, Myles ; Johansson, Erin ; van Hest, Naomi ; Annemans, Lieven ; Bays, Harold ; Wilding, John P. H. ; Spaepen, Erik ; Upadhyay, Navneet

PURPOSE:

This study evaluated the cost-effectiveness (from the United States [US] societal perspective) of tirzepatide at its maximum-tolerated-dose (MTD) compared to semaglutide (MTD), both administered adjunct to a reduced-calorie diet and increased physical activity. The analysis focused on individuals with obesity (body mass index [BMI] ≥ 30 kg/m²), or overweight (BMI ≥27 to <30 kg/m² + ≥1 obesity-related complication), using data from the head-to-head Phase-3 SURMOUNT-5 trial (patients without type 2 diabetes [T2D]).

PATIENTS AND METHODS:

This patient-level simulation modeling study assessed the cost and long-term clinical outcomes of tirzepatide (MTD) versus semaglutide (MTD), using data from the SURMOUNT-5 trial population. The modeled population were at risk of developing obesity-related complications including cardiovascular disease (CVD) and obstructive sleep apnea (OSA), amongst others. These outcomes were modeled using cardiometabolic parameters including weight, systolic blood pressure, high-density lipoprotein, glycated hemoglobin (HbA1c) and total cholesterol, by assessing their impact on healthcare and wider societal costs, quality of life, and mortality. Incremental cost-effectiveness ratios (ICERs; cost/quality-adjusted life year [QALY]) and incremental net health benefit (iNHBs) were calculated, and uncertainty was assessed through sensitivity and scenario analyses.

RESULTS:

Tirzepatide (MTD) was estimated to be less costly and more efficacious compared to semaglutide (MTD) with per patient cost savings of $41,688, 0.506 QALYs gained and positive iNHB of 0.784, indicating a net health benefit for tirzepatide. The model predicted that per 1,000 patients, 70 fewer patients will develop T2D, 10 fewer will develop CVD with tirzepatide (MTD) and patients spend 3.07 more years living with moderate/severe OSA when treated with semaglutide (MTD).

CONCLUSION:

Based on this simulation model, using head-to-head SURMOUNT-5 trial data, tirzepatide (MTD) had lower total costs and higher QALYs compared to semaglutide (MTD). This supports that tirzepatide (MTD) is a cost-effective treatment option for individuals with obesity or overweight compared to semaglutide (MTD).

2,026

News (Medical) associated with Tirzepatide

12 Aug 2026

·www.prnewswire.com

Aurisco Pharmaceutical is the First Generic Oligonucleotide Manufacturer in the World successfully inspected by USFDA

SHANGHAI, Aug. 12, 2026 /PRNewswire/ -- Aurisco Pharmaceutical, a leading global Oligonucleotide and Peptide (TIDES) manufacturer, announced today that its site in Yangzhou, China has passed the USFDA inspection as the first generic Oligonucleotide API manufacturer in the world. The USFDA pre-approval inspection for Inclisiran Sodium inspection was carried out for 5 days (15-19.Jun.2026), as initially planned, and covered cGMP compliance inspection for oligonucleotides, GLP-1 peptides (such as Semaglutide and Tirzepatide) and small molecules. Continue Reading cGMP Oligonucleotide Manufacturing at Yangzhou Aurisco. The EIR letter confirmed Aurisco successfully addressed the inspector's observations with an approved CAPA plan. The inspector was satisfied with the facilities and complimented Aurisco on its GMP system and documents, inspection organization and the knowledge of its team members. Dr. Wang Guoping, site GM, said "This was the first FDA inspection to a generic oligonucleotide manufacturer. We are collaborating with agencies worldwide to establish pathways for generic TIDES". This inspection opens the door for future generic oligonucleotides (Inclisiran, Vutrisiran, Nusinersen, Eplontersen, etc.). The site had been successfully inspected by USFDA in 2023 and offers CDMO services and generic APIs. Dr. Li Jinliang, Board Director, said "This inspection marks the beginning of a new of safe and affordable oligonucleotides patients. I congratulate Aurisco's team for being so committed and thank our customers and shareholders for their trust and support." About Aurisco Aurisco Pharmaceutical Co., Ltd. (SSE: 605116) serves global markets since 1998. With 6 R&D centers, 4 manufacturing sites and sales offices in USA, Portugal, India and Brazil, the company focuses on complex products. With 100+ patents filled worldwide and 300 scientists, the company offers an IP safe and a cGMP and ESG compliant environment for NCEs and complex generics. Being Ecovadis Gold ranked, Aurisco has joined the SBTi, M2030 and the SPP. Aurisco passed RX360 supply chain security inspection and has been audited by the Pharmaceutical Supply Chain Initiative (PSCI). For further information, please visit and follow us on LinkedIn or contact [email protected]. Contact: Rafael Antunes, [email protected], M. +351 919 387 143 SOURCE Aurisco Pharmaceutical 21% more press release views with Request a Demo

Oligonucleotide

12 Aug 2026

·www.prnewswire.com

U.S. News & World Report Releases Debut Ratings for the 2026-2027 Best GLP-1 Telehealth Platforms

Inaugural ratings evaluate leading online GLP-1 platforms to help consumers make informed decisions in the fast-growing weight management market. WASHINGTON, Aug. 12, 2026 /PRNewswire/ -- U.S. News & World Report, the global authority in healthcare decision support, today announced its debut ratings for the Best GLP-1 Telehealth Platforms. The inaugural ratings evaluate 20 online platforms offering FDA-approved, brand-name GLP-1 medications – such as Wegovy, Zepbound, Ozempic and Foundayo – to help consumers safely and confidently navigate the expanding digital weight management marketplace. Navigating prescription weight loss requires personalized medical guidance, and patients should partner with a healthcare provider to ensure any online platform meets their specific clinical needs. The release comes as GLP-1 medications continue to reshape the healthcare landscape. In a U.S. News survey published in January 2026 on Top Health Trends for 2026, 52% of health and nutrition experts indicated the expanded use of GLP-1s as the trend that would make the most significant impact on public health this year. With demand for GLP-1's surging, millions of Americans are turning to online telehealth platforms to access these medications. However, navigating complicated fee structures, varying levels of doctor oversight and complex insurance processes makes finding transparent and reliable options difficult. U.S. News' new ratings cut through the noise by evaluating platforms on clinical rigor, pricing transparency, insurance concierge support and long-term care management. "Finding transparent cost details and reliable decision support data is often confusing to consumers," said Gretel Schueller, managing editor of health at U.S. News. "U.S. News' GLP-1 telehealth platform ratings were created to bring clarity to a complex marketplace. By thoroughly evaluating platforms across six unique patient-focused pillars, we aim to help American consumers confidently choose a platform – in consultation with their doctor – that aligns with their budget and health goals." Top-Rated GLP-1 Telehealth Platforms Out of 20 platforms evaluated, 11 achieved top ratings from U.S. News based on a comprehensive 5-point scale: Amazon One Medical Found Fridays Ivim Health LifeMD Mochi Health Noom PlushCare Remedy Meds Ro WeightWatchers Top Performers by Category U.S. News recognized individual standouts across four specific categories: Methodology U.S. News evaluated 20 telehealth platforms offering FDA-approved, brand-name GLP-1s using 14,161 data points and feedback from more than 1,200 active GLP-1 telehealth users. These platforms were scored on a 5-point scale across six key pillars: clinical support (25%), screening rigor (20%), transparency (17%), insurance assistance (15%), supplemental care (13%), and overall customer satisfaction (10%). Companies that only offer compounded GLP-1 medications were not included in our analysis. However, some of the rated platforms offer both branded and compounded. In those cases, U.S. News' ratings only evaluate the aspects of the platform relating to FDA-approved, brand-name GLP-1 medications. When considering GLP-1 treatment, individuals should always consult with a medical provider. To find a primary care physician or specialist in your area, visit the U.S. News Doctor Directory to guide your care decisions in consultation with your doctor. To explore the full ratings and methodology, visit Best GLP-1 Telehealth Platforms. For additional information on treatment options, check out U.S. News' GLP-1 Consumer Guide. About U.S. News & World Report U.S. News & World Report is the global leader for journalism that empowers consumers, citizens, business leaders and policy officials to make confident decisions in all aspects of their lives and communities. A multifaceted media company, U.S. News provides unbiased rankings, independent reporting and analysis, and consumer advice to millions of people on USNews.com each month. A pillar in Washington for more than 90 years, U.S. News is the trusted home for in-depth and exclusive insights on education, health, politics, the economy, insurance, personal finance, travel, automobiles, real estate, careers and consumer products and services. SOURCE U.S. News & World Report, L.P. 21% more press release views with Request a Demo

12 Aug 2026

·www.biospace.com

Mapi Pharma Announces Initial Phase I/IIa Clinical Results Supporting Continued Development of Once-Monthly Cariprazine Depot

NESS ZIONA, Israel, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd. (“Mapi” or the “Company”), a late-stage clinical biopharmaceutical company specializing in long-acting injectable therapies, today announced initial clinical results from its on-going Phase I/IIa trial that support continued development of once-monthly Cariprazine Depot. Cariprazine is a well-established atypical antipsychotic approved for the treatment of schizophrenia, bipolar I disorder and major depressive disorder (MDD). It is currently available only as a once-daily oral therapy. However, clinicians treating chronic psychiatric conditions generally prefer long-acting injectable (LAI) formulations of anti-psychotic medications, due to their ability to improve treatment adherence, reduce relapse risk and simplify long-term disease management. Mapi Pharma is developing Cariprazine Depot , a once-monthly subcutaneous (SC) long-acting injectable formulation of cariprazine, using its proprietary depot technology. Designed to provide sustained drug release over one month, Cariprazine Depot has the potential to address an important unmet need by offering a convenient long-acting treatment option for patients with schizophrenia, bipolar disorder and MDD. Vraylar cariprazine capsules (marketed in the US by AbbVie and covered by a patent that will expire in 2029) generated net revenues of $3.6 billion in global sales in 2025, highlighting the significant commercial potential for an LAI formulation. Phase I/IIa Clinical Study Design ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); The ongoing prospective, dose-escalating, open-label, multi-center, Phase I/IIa study is designed to evaluate the pharmacokinetics (PK), safety and tolerability of once-monthly SC injections of Cariprazine Depot in subjects eligible for treatment with oral cariprazine. Following a washout period, participants received a single 22 mg subcutaneous injection of Cariprazine Depot. For more information on the design refer to ClinicalTrials.gov: NCT07185815. Top-Line Results Top-line results from Cohort 1 are now available. The results demonstrated that Cariprazine Depot exhibited a safety pro with the established safety pro oral cariprazine. Key findings included: No serious adverse events (SAEs) were reported. All treatment-related adverse events associated with Cariprazine Depot were mild. Injection site reactions (ISRs) were mild, with injection site pain resolving rapidly (mean duration of less than one day). Treatment-related non-ISR adverse events occurred in fewer participants and were less frequent with Cariprazine Depot than with oral cariprazine. Each patient was treated at the beginning with oral cariprazine, and their data was analyzed. Overall, once-monthly Cariprazine Depot administered as add-on therapy was safe and well tolerated. These encouraging results support the continued clinical development of Cariprazine Depot as a potential long-acting treatment option for patients requiring cariprazine therapy. Ehud Marom, Chairman and Chief Executive Officer, Mapi Pharma, said, “We are excited to announce the excellent clinical results and are planning to submit an IND to the U.S. FDA by the end of 2026 with a partner who is expected to support the Phase 3 and lead marketing. Mapi will be responsible for drug manufacturing for clinical studies and the commercial supply from it’s GMP approved facilities. If successful in Phase 3, an NDA submission is planned for 2029”. About Mapi Pharma Mapi Pharma is a clinical-stage pharmaceutical company focused on the development of high-value, complex injectable therapies with significant barriers to entry. The Company’s portfolio includes long-acting depot formulations targeting large and growing markets, including central nervous system disorders and metabolic diseases. Key pipeline programs include long-acting formulations of Cariprazine, as well as GLP-1 therapies such as Semaglutide and Tirzepatide for diabetes and weight management. Mapi is also developing an AB-rated generic version of Naltrexone (Vivitrol ® ) and markets generic versions of Fingolimod (Gilenya ® ) and Apremilast (Otezla ® ) in select regions. Mapi combines deep expertise in chemistry, pharmaceutical development, and clinical execution with a strong intellectual property portfolio, including numerous granted patents primarily focused on formulations. The Company operates dedicated R&D and aseptic manufacturing facilities for long-acting injectable dosage forms. For more information, please visit Contacts: Alex Mogle Vice President, Corporate Development Mapi Pharma +972 52 6080297 alex@mapi-pharma.com Brian Ritchie Managing Director LifeSci Advisors, LLC britchie@lifesciadvisors.com

Clinical ResultNDAPhase 3

100 Deals associated with Tirzepatide

External Link

KEGG	Wiki	ATC	Drug Bank
D11360	Tirzepatide	-	DB15171

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Obesity Hypoventilation Syndrome	China	Eli Lilly Suzhou Pharmaceutical Co. Ltd.	30 Jun 2025
Sleep Apnea, Obstructive	United States	Eli Lilly & Co.	20 Dec 2024
Obesity	United States	Eli Lilly & Co.	08 Nov 2023
Overweight	United States	Eli Lilly & Co.	08 Nov 2023
Weight Gain	Australia	Eli Lilly Australia Pty Ltd.	23 Dec 2022
Diabetes Mellitus, Type 2	United States	Eli Lilly & Co.	13 May 2022

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Heart failure with normal ejection fraction	NDA/BLA	China	Eli Lilly & Co.	22 Nov 2024
Reduced ejection fraction co-occurrent and due to chronic heart failure	NDA/BLA	European Union	Eli Lilly & Co.	-
Metabolic dysfunction-associated steatotic liver disease	Phase 3	United States	Eli Lilly & Co.	16 Oct 2025
Colitis, Ulcerative	Phase 3	United States	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Austria	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Belgium	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Brazil	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Bulgaria	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Canada	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Czechia	Eli Lilly & Co.	26 Jun 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04255433 (SURPASS-CVOT \| SURPASS, CTgov)	Phase 3	Diabetes Mellitus, Type 2	13,299	Dulaglutide	ttwwkzwyjj = rmpgdfyllv ynvistithz (utsqysgqxc, ngkfboxxsa - jfpqchllmb) View more	-	08 Jul 2026
NCT05963022 (SURPASS-CN-MONO, Pubmed \| Med)	Phase 3	Early-onset type II diabetes	206	5 mg Tirzepatide	wtybtgudli(lhdyfaspfz) = szvuymbzze uwtdfqaqqp (xyrlkjlwcl ) View more	Positive	01 Jul 2026
				10 mg Tirzepatide	wtybtgudli(lhdyfaspfz) = ilnodhiqrn uwtdfqaqqp (xyrlkjlwcl ) View more
NCT05260021 (SURPASS-PEDS, ADA2026)	Phase 3	Diabetes Mellitus, Type 2	99	Tirzepatide 5 mg	rsdhtgwyjy(eexxvfxett) = tutrjhvrge zdqnajxedg (sgcctwbqzm )	Positive	20 Jun 2026
				Placebo	rsdhtgwyjy(eexxvfxett) = pjfjasqiai zdqnajxedg (sgcctwbqzm )
ADA2026	Not Applicable	Diabetes Mellitus, Type 2	71	Tirzepatide (Type 2 Diabetes Mellitus)	lmnxufioym(mpkkpjartt) = Gastrointestinal adverse events were common (59.2%) but predominantly mild to moderate. No severe hypoglycemia or serious adverse events occurred. hqawcjfvlp (huccwfatzz )	Positive	20 Jun 2026
ADA2026	Not Applicable	Overweight \| Obesity	181	Tirzepatide	orgkkkmnpy(ghiszrbzck) = ekcyetdkud icivnozyib (fpaprostjz, 80.7 - 91.2) View more	Positive	20 Jun 2026
ADA2026	Not Applicable	Diabetes Mellitus, Type 2 \| Peripheral Arterial Disease	24,374	Tirzepatide	kqgvpeowci(zizyzabbbx): RR = 0.65 (95.0% CI, 0.45 - 0.92), P-Value = 0.015	Positive	20 Jun 2026
				Injectable Semaglutide
ADA2026	Not Applicable	Diabetes Mellitus, Type 2	12,500	Tirzepatide	tysnlanwrf(cgnztqnnfc): RR = 1.08 (95.0% CI, 0.97 - 1.2)	Positive	20 Jun 2026
				Semaglutide
NCT06588296 (TOGETHER-PSA, EULAR2026)	Phase 3	Arthritis, Psoriatic	271	IXEKIZUMAB AND CONCOMITANT TIRZEPATIDE	ofkbjdwoav(arcvtuipei) = ihzazbbfaq icepqnlvwe (pckytmhfji ) View more	Positive	11 Jun 2026
				IXEKIZUMAB	ofkbjdwoav(arcvtuipei) = wjkuhnmvlq icepqnlvwe (pckytmhfji ) View more
EULAR2026	Not Applicable	Arthritis, Psoriatic	73	Tirzepatide+biologic	iparlpomxs(rlhasqpjxi) = iomzrvxahp wqofipuzqo (emoqqcoelx ) View more	Positive	11 Jun 2026
				biologic	tqbjfnigqf(vbtkurwlqx) = keikjvwvsq gpqplzgyzk (qudqznckrr ) View more
NCT04255433 (Pubmed \| JAMA Cardiol)	Phase 3	Cardiovascular Diseases \| Diabetes Mellitus, Type 2	13,165	Tirzepatide	aefqsoykah(qglbmjnvph) = rdusymlwpb gckgjtymjr (gjkqvfgxly ) View more	Positive	01 Jun 2026
				Dulaglutide	aefqsoykah(qglbmjnvph) = xfukkhhubr gckgjtymjr (gjkqvfgxly ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis